Boston Pharmaceuticals products

BOS-228 is a novel monobactam for infections caused by multidrug-resistant carbapenem-resistant Enterobacteriaceae.

BOS-475 is a selective BET (bromodomain and extra terminal) inhibitor. BOS-475 potently inhibits multiple clinically validated pathways (IL-12/IL-23-p40, Th17 cytokines and TNF) relevant to psoriasis pathophysiology. BOS-475 demonstrates broad inhibitory activities on other key disease-relevant immune-inflammatory mediators such as MCP-1, IL-6, and CXCL10 & 11. Topical BOS-475 is a potential treatment for psoriasis and other inflammatory skin diseases.

BOS161721 (avizakimab) is a fully human anti-IL-21 antibody.

BOS-572 is a broad-spectrum serine beta-lactamase inhibitor (BLI) of the diazabicyclooctane (DBO) class.

BOS-421 is a highly selective, brain penetrant RIPK1 inhibitor.